Elizabeth Crowne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Elizabeth Crowne has a total of 151 co-authors. Here are the top co-authors by number of shared publications:
Christina Wei
8 shared publications- Julian Paul Hamilton-Shield
Department of Paediatric Endocrinology and Diabetes, Bristol Royal Hospital for Children, Bristol, UK
4 shared publications - Rathi Prasad
Centre for Endocrinology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
4 shared publications - Avinaash Maharaj
Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University , London EC1M 6BQ
3 shared publications - Federica Buonocore
Genetics and Genomic Medicine Research and Teaching Department, UCL Great Ormond Street Institute of Child Health, University College London, London, UK
3 shared publications Karin Bradley
3 shared publications
Latest Publications
- 20 October 2026
- Published by S. Karger AG in Hormone Research in Paediatrics
Familial 46,XX Ovotesticular Differences in Sex Development Associated With an NR5A1 p.Arg92Trp Variant
Introduction: NR5A1 encodes steroidogenic factor 1 (SF-1), a key regulator of adrenal and gonadal development, steroidogenesis, AMH transcription, and the balance between pro-testicular and pro-ovarian pathways. The recurrent NR5A1 c.274C>T (p.Arg92Trp) variant is associated with SRY-negative 46,XX testicular and ovotesticular differences in sex development (DSD), but intrafamilial expression remains difficult to predict. Case Presentation We report a rare multigenerational familial presentation of SRY-negative 46,XX ovotesticular DSD associated with the heterozygous NR5A1 p.Arg92Trp variant. The proband was noted antenatally to have atypical genital development. Antenatal karyotyping confirmed a 46,XX, SRY-negative result. At birth, the proband had clitoromegaly, posterior labioscrotal fusion, a perineal urethral opening, absent vaginal opening, and palpable labioscrotal gonads. Testosterone, anti mullerian hormone (AMH), and inhibin B were elevated, consistent with functioning testicular tissue, while adrenal investigations were normal. Imaging and laparoscopy showed mixed Müllerian and Wolffian structures, and gonadal histology confirmed ovarian primordial follicles. The family history was notable for DSD in the mother’s sister, who had undergone childhood genital surgery and gonadectomy, with histology showing intratubular germ cell neoplasia. She was the first family member found to carry the NR5A1 p.Arg92Trp variant, prompting targeted testing in the proband and her mother, both of whom were positive. The variant was subsequently identified in the maternal grandmother and in the proband’s older 46,XX, SRY-negative brother, who was raised male and had typical male external genitalia with bilateral scrotal gonads; the mother’s brother tested negative. The mother had previously been treated for a unilateral ovarian germ cell tumour. These findings demonstrate marked intrafamilial variability and highlight the importance of family-history-led genetic testing, tumour-risk assessment, and long-term multidisciplinary follow-up. Conclusion: This family captures the striking phenotypic breadth of NR5A1 p.Arg92Trp within a single pedigree and illustrates the role of NR5A1 as a developmental regulator of gonadal fate and AMH-mediated ductal differentiation. It emphasises the need for cautious individualised management, tumour surveillance, long-term follow-up, genetic counselling, and psychological support.
- 20 October 2026
- Published by S. Karger AG in Hormone Research in Paediatrics
Familial 46,XX Ovotesticular Differences in Sex Development Associated With an NR5A1 p.Arg92Trp Variant
Introduction: NR5A1 encodes steroidogenic factor 1 (SF-1), a key regulator of adrenal and gonadal development, steroidogenesis, AMH transcription, and the balance between pro-testicular and pro-ovarian pathways. The recurrent NR5A1 c.274C>T (p.Arg92Trp) variant is associated with SRY-negative 46,XX testicular and ovotesticular differences in sex development (DSD), but intrafamilial expression remains difficult to predict. Case Presentation We report a rare multigenerational familial presentation of SRY-negative 46,XX ovotesticular DSD associated with the heterozygous NR5A1 p.Arg92Trp variant. The proband was noted antenatally to have atypical genital development. Antenatal karyotyping confirmed a 46,XX, SRY-negative result. At birth, the proband had clitoromegaly, posterior labioscrotal fusion, a perineal urethral opening, absent vaginal opening, and palpable labioscrotal gonads. Testosterone, anti mullerian hormone (AMH), and inhibin B were elevated, consistent with functioning testicular tissue, while adrenal investigations were normal. Imaging and laparoscopy showed mixed Müllerian and Wolffian structures, and gonadal histology confirmed ovarian primordial follicles. The family history was notable for DSD in the mother’s sister, who had undergone childhood genital surgery and gonadectomy, with histology showing intratubular germ cell neoplasia. She was the first family member found to carry the NR5A1 p.Arg92Trp variant, prompting targeted testing in the proband and her mother, both of whom were positive. The variant was subsequently identified in the maternal grandmother and in the proband’s older 46,XX, SRY-negative brother, who was raised male and had typical male external genitalia with bilateral scrotal gonads; the mother’s brother tested negative. The mother had previously been treated for a unilateral ovarian germ cell tumour. These findings demonstrate marked intrafamilial variability and highlight the importance of family-history-led genetic testing, tumour-risk assessment, and long-term multidisciplinary follow-up. Conclusion: This family captures the striking phenotypic breadth of NR5A1 p.Arg92Trp within a single pedigree and illustrates the role of NR5A1 as a developmental regulator of gonadal fate and AMH-mediated ductal differentiation. It emphasises the need for cautious individualised management, tumour surveillance, long-term follow-up, genetic counselling, and psychological support.
- Open Access
- 5 February 2026
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 39 (3) , 217-235
Impact of eating behaviour on craniopharyngioma-associated obesity
Craniopharyngiomas are low-grade suprasellar intracranial tumours associated with hypothalamic–pituitary axis dysfunction and obesity. This scoping review aimed to explore the potential impact of hyperphagic eating behaviour and appetitive factors on the development of craniopharyngioma-associated obesity and to identify areas for future intervention. PRISMA-ScR and JBI methodology was followed. Five databases and two trial registries were searched. All published studies of patients with childhood or adult-onset craniopharyngioma that addressed eating behaviours in conjunction with pharmaceutical/surgical interventions, neuroimaging, endocrine responses, energy expenditure, sleep and/or neuropsychology were included in this review. Evidence surrounding eating behaviours in craniopharyngioma patients was sparce with only 10 of the 50 included papers using validated eating behaviour assessments. Eating behaviour was included as a primary outcome (n=7), secondary outcome (n=12) or commented on without formal measurement (n=31). Few studies included patients with adult-onset craniopharyngioma (n=8) or compared patients with craniopharyngioma with and without obesity (n=2), and no papers were identified that attempted to modify eating behaviours as an intervention for craniopharyngioma-related obesity. Further understanding of eating behaviour in craniopharyngioma patients through longer-term research with validated measures will improve our understanding of mechanisms underlying craniopharyngioma-associated obesity and inform clinical practice by allowing treatments tailored for patient-centred care.
- 5 February 2026
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 39 (3) , 217-235
Open AccessImpact of eating behaviour on craniopharyngioma-associated obesity
Craniopharyngiomas are low-grade suprasellar intracranial tumours associated with hypothalamic–pituitary axis dysfunction and obesity. This scoping review aimed to explore the potential impact of hyperphagic eating behaviour and appetitive factors on the development of craniopharyngioma-associated obesity and to identify areas for future intervention. PRISMA-ScR and JBI methodology was followed. Five databases and two trial registries were searched. All published studies of patients with childhood or adult-onset craniopharyngioma that addressed eating behaviours in conjunction with pharmaceutical/surgical interventions, neuroimaging, endocrine responses, energy expenditure, sleep and/or neuropsychology were included in this review. Evidence surrounding eating behaviours in craniopharyngioma patients was sparce with only 10 of the 50 included papers using validated eating behaviour assessments. Eating behaviour was included as a primary outcome (n=7), secondary outcome (n=12) or commented on without formal measurement (n=31). Few studies included patients with adult-onset craniopharyngioma (n=8) or compared patients with craniopharyngioma with and without obesity (n=2), and no papers were identified that attempted to modify eating behaviours as an intervention for craniopharyngioma-related obesity. Further understanding of eating behaviour in craniopharyngioma patients through longer-term research with validated measures will improve our understanding of mechanisms underlying craniopharyngioma-associated obesity and inform clinical practice by allowing treatments tailored for patient-centred care.
- 13 July 2023
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109 (1) , e336-e346
Quality of Life in Children and Young People With Congenital Adrenal Hyperplasia—UK Nationwide Multicenter Assessment
Context: Quality of life (QoL) has been inconsistently reported in children and young people (CYP) with congenital adrenal hyperplasia (CAH). Objective: Assess QoL in CYP with CAH in the UK alongside biometric and androgen profiles. Design: To define the evidence base for health care delivery, we conducted a cross-sectional study in CYP with CAH in the UK. Questionnaire results were compared with normative data and between groups, and modelled for association with sex, height, weight, body mass index, or steroid biomarkers of CAH control. Setting: Tertiary care in 14 UK centers. Patients: Results from 104 patients, 55% female, mean age 12.7 years (SD 3.0), paired responses from parents. Interventions: Strengths and Difficulties questionnaire (SDQ) and pediatric QoL questionnaire. Main Outcome Measure: Total QoL scores as assessed by SDQ and a pediatric QoL questionnaire in comparison to normative data. Results: Total scores were worse in parents than normative data, but similar in patients. Patient QoL was rated better in social functioning but worse in emotional, school, and peer domains by patients, and worse in total scores and domains of peer problems, and psychosocial, emotional, and school functioning by parents. Parents consistently scored QoL of their children lower than their child. Larger height-SD score and lower weight-SD score were associated with better QoL. Girls with lower steroid biomarkers had worse SDQ scores. Conclusions: In CYP with CAH, reduced height, increased weight, and hormonal biomarkers consistent with overtreatment were associated with worse QoL; addressing these problems should be prioritized in clinical management. Clinical Trials Registration Number: SCH/15/088
- 13 July 2023
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109 (1) , e336-e346
Quality of Life in Children and Young People With Congenital Adrenal Hyperplasia—UK Nationwide Multicenter Assessment
Context: Quality of life (QoL) has been inconsistently reported in children and young people (CYP) with congenital adrenal hyperplasia (CAH). Objective: Assess QoL in CYP with CAH in the UK alongside biometric and androgen profiles. Design: To define the evidence base for health care delivery, we conducted a cross-sectional study in CYP with CAH in the UK. Questionnaire results were compared with normative data and between groups, and modelled for association with sex, height, weight, body mass index, or steroid biomarkers of CAH control. Setting: Tertiary care in 14 UK centers. Patients: Results from 104 patients, 55% female, mean age 12.7 years (SD 3.0), paired responses from parents. Interventions: Strengths and Difficulties questionnaire (SDQ) and pediatric QoL questionnaire. Main Outcome Measure: Total QoL scores as assessed by SDQ and a pediatric QoL questionnaire in comparison to normative data. Results: Total scores were worse in parents than normative data, but similar in patients. Patient QoL was rated better in social functioning but worse in emotional, school, and peer domains by patients, and worse in total scores and domains of peer problems, and psychosocial, emotional, and school functioning by parents. Parents consistently scored QoL of their children lower than their child. Larger height-SD score and lower weight-SD score were associated with better QoL. Girls with lower steroid biomarkers had worse SDQ scores. Conclusions: In CYP with CAH, reduced height, increased weight, and hormonal biomarkers consistent with overtreatment were associated with worse QoL; addressing these problems should be prioritized in clinical management. Clinical Trials Registration Number: SCH/15/088
- 7 June 2022
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 35 (1) , 56-60
Why do parents recommend clitoral surgery? Parental perception of the necessity, benefit, and cost of early childhood clitoral surgery for congenital adrenal hyperplasia (CAH)
Historically, medical management of Congenital Adrenal Hyperplasia (CAH) in girls typically involved feminising surgery, which meant reducing the size and/or visibility of the enlarged clitoris. This practice may have become less routine but remains a common response to genital differences associated with CAH. Parents typically give permission for the child to undergo surgery in early childhood and recommend other parents facing a similar situation do the same. The current report is based on a qualitative content analysis of interviews with sixteen parents whose daughters with CAH had undergone one of two forms of clitoral surgery. We observed that: (i) some parents were initially unconcerned about their child’s genital presentation; (ii) in general, clitoral surgery was considered as a readily available and natural response to the child’s bodily difference; (iii) the parents acknowledged that there would be some risk but anticipated various benefits; and (iv) there was an absence of ethical considerations when the parents evaluated the various effects of surgery afterwards. We conclude from our analysis that parents of girls with CAH may not receive psychologically and ethically informed counselling to encourage critical reflections prior to authorizing genital surgery.
- 7 June 2022
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 35 (1) , 56-60
Why do parents recommend clitoral surgery? Parental perception of the necessity, benefit, and cost of early childhood clitoral surgery for congenital adrenal hyperplasia (CAH)
Historically, medical management of Congenital Adrenal Hyperplasia (CAH) in girls typically involved feminising surgery, which meant reducing the size and/or visibility of the enlarged clitoris. This practice may have become less routine but remains a common response to genital differences associated with CAH. Parents typically give permission for the child to undergo surgery in early childhood and recommend other parents facing a similar situation do the same. The current report is based on a qualitative content analysis of interviews with sixteen parents whose daughters with CAH had undergone one of two forms of clitoral surgery. We observed that: (i) some parents were initially unconcerned about their child’s genital presentation; (ii) in general, clitoral surgery was considered as a readily available and natural response to the child’s bodily difference; (iii) the parents acknowledged that there would be some risk but anticipated various benefits; and (iv) there was an absence of ethical considerations when the parents evaluated the various effects of surgery afterwards. We conclude from our analysis that parents of girls with CAH may not receive psychologically and ethically informed counselling to encourage critical reflections prior to authorizing genital surgery.
- 7 April 2022
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 96 (2) , 222-227
Psychological Care of Children and Families with Variations or Differences in Sex Development
The paediatric clinical psychology literature provides applicable evidence for use in specialist healthcare settings and services. The general approach of psychological care of children and families with paediatric conditions is recognizable as preventative and destigmatizing, aimed to maximize personal agency with shared responsibility for achieving best outcomes via multi-professional teamwork. Recent commentaries regarding healthcare for children with differences in sex development (DSD) have noted service-level pitfalls, including poor teamwork and underuse of early and integrated psychological intervention. Psychological research regarding the variously termed DSD, variations in sex development, variation in sex characteristics, or intersex has historically centred around the assessment of sex differences, gender identity, and the impact of including hormone influences on brain and behaviour. Psychological research in this specialist area has not focussed on the evaluation of specific clinical interventions or psychotherapeutic models but has investigated psychological aspects of multi-professional healthcare provision. There are new goals for psychological care of children with variations or differences in sex development (V/DSD). These require a framework of good communication to enable those receiving care to come to know and articulate their own hopes for treatment and support. Paediatric psychological intervention studies involving larger clinical groups such as diabetes provide evidence applicable to DSD populations. A risk of stigma is recognized as inherent to some physical interventions within routine paediatric care of people with V/DSD. Psychological care and intervention should be aimed at minimizing these risks via questioning and examining their assumed need. Psychological approaches can provide a foundation for ethical and rights-based multi-professional care of children with V/DSD.
- 7 April 2022
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 96 (2) , 222-227
Psychological Care of Children and Families with Variations or Differences in Sex Development
The paediatric clinical psychology literature provides applicable evidence for use in specialist healthcare settings and services. The general approach of psychological care of children and families with paediatric conditions is recognizable as preventative and destigmatizing, aimed to maximize personal agency with shared responsibility for achieving best outcomes via multi-professional teamwork. Recent commentaries regarding healthcare for children with differences in sex development (DSD) have noted service-level pitfalls, including poor teamwork and underuse of early and integrated psychological intervention. Psychological research regarding the variously termed DSD, variations in sex development, variation in sex characteristics, or intersex has historically centred around the assessment of sex differences, gender identity, and the impact of including hormone influences on brain and behaviour. Psychological research in this specialist area has not focussed on the evaluation of specific clinical interventions or psychotherapeutic models but has investigated psychological aspects of multi-professional healthcare provision. There are new goals for psychological care of children with variations or differences in sex development (V/DSD). These require a framework of good communication to enable those receiving care to come to know and articulate their own hopes for treatment and support. Paediatric psychological intervention studies involving larger clinical groups such as diabetes provide evidence applicable to DSD populations. A risk of stigma is recognized as inherent to some physical interventions within routine paediatric care of people with V/DSD. Psychological care and intervention should be aimed at minimizing these risks via questioning and examining their assumed need. Psychological approaches can provide a foundation for ethical and rights-based multi-professional care of children with V/DSD.
- Open Access
- 11 May 2021
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 5 (8) , bvab086
Genetic Analysis of Pediatric Primary Adrenal Insufficiency of Unknown Etiology: 25 Years’ Experience in the UK
Context Although primary adrenal insufficiency (PAI) in children and young people is often due to congenital adrenal hyperplasia (CAH) or autoimmunity, other genetic causes occur. The relative prevalence of these conditions is poorly understood. Objective We investigated genetic causes of PAI in children and young people over a 25 year period. Design, Setting and Participants Unpublished and published data were reviewed for 155 young people in the United Kingdom who underwent genetic analysis for PAI of unknown etiology in three major research centers between 1993 and 2018. We pre-excluded those with CAH, autoimmune, or metabolic causes. We obtained additional data from NR0B1 (DAX-1) clinical testing centers. Intervention and Outcome Measurements Genetic analysis involved a candidate gene approach (1993 onward) or next generation sequencing (NGS; targeted panels, exomes) (2013-2018). Results A genetic diagnosis was reached in 103/155 (66.5%) individuals. In 5 children the adrenal insufficiency resolved and no genetic cause was found. Pathogenic variants occurred in 11 genes: MC2R (adrenocorticotropin receptor; 30/155, 19.4%), NR0B1 (DAX-1; 7.7%), CYP11A1 (7.7%), AAAS (7.1%), NNT (6.5%), MRAP (4.5%), TXNRD2 (4.5%), STAR (3.9%), SAMD9 (3.2%), CDKN1C (1.3%), and NR5A1/steroidogenic factor-1 (SF-1; 0.6%). Additionally, 51 boys had NR0B1 variants identified through clinical testing. Although age at presentation, treatment, ancestral background, and birthweight can provide diagnostic clues, genetic testing was often needed to define the cause. Conclusions PAI in children and young people often has a genetic basis. Establishing the specific etiology can influence management of this lifelong condition. NGS approaches improve the diagnostic yield when many potential candidate genes are involved.
- 11 May 2021
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 5 (8) , bvab086
Open AccessGenetic Analysis of Pediatric Primary Adrenal Insufficiency of Unknown Etiology: 25 Years’ Experience in the UK
Context Although primary adrenal insufficiency (PAI) in children and young people is often due to congenital adrenal hyperplasia (CAH) or autoimmunity, other genetic causes occur. The relative prevalence of these conditions is poorly understood. Objective We investigated genetic causes of PAI in children and young people over a 25 year period. Design, Setting and Participants Unpublished and published data were reviewed for 155 young people in the United Kingdom who underwent genetic analysis for PAI of unknown etiology in three major research centers between 1993 and 2018. We pre-excluded those with CAH, autoimmune, or metabolic causes. We obtained additional data from NR0B1 (DAX-1) clinical testing centers. Intervention and Outcome Measurements Genetic analysis involved a candidate gene approach (1993 onward) or next generation sequencing (NGS; targeted panels, exomes) (2013-2018). Results A genetic diagnosis was reached in 103/155 (66.5%) individuals. In 5 children the adrenal insufficiency resolved and no genetic cause was found. Pathogenic variants occurred in 11 genes: MC2R (adrenocorticotropin receptor; 30/155, 19.4%), NR0B1 (DAX-1; 7.7%), CYP11A1 (7.7%), AAAS (7.1%), NNT (6.5%), MRAP (4.5%), TXNRD2 (4.5%), STAR (3.9%), SAMD9 (3.2%), CDKN1C (1.3%), and NR5A1/steroidogenic factor-1 (SF-1; 0.6%). Additionally, 51 boys had NR0B1 variants identified through clinical testing. Although age at presentation, treatment, ancestral background, and birthweight can provide diagnostic clues, genetic testing was often needed to define the cause. Conclusions PAI in children and young people often has a genetic basis. Establishing the specific etiology can influence management of this lifelong condition. NGS approaches improve the diagnostic yield when many potential candidate genes are involved.
- 1 October 2020
- Published by Elsevier in Current Opinion in Endocrine and Metabolic Research
- Vol. 14, 112-116
Novel therapies for childhood cancer and impact on puberty
- 1 October 2020
- Published by Elsevier in Current Opinion in Endocrine and Metabolic Research
- Vol. 14, 112-116
Novel therapies for childhood cancer and impact on puberty
- Open Access
- 30 October 2018
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 3 (1) , 201-221
Predicted Benign and Synonymous Variants in CYP11A1 Cause Primary Adrenal Insufficiency Through Missplicing
Primary adrenal insufficiency (PAI) is a potentially life-threatening condition that can present with non-specific features and can be difficult to diagnose. Here, we undertook next-generation sequencing in a cohort of children and young adults with PAI of unknown etiology from around the world and identified a heterozygous missense variant (rs6161, c.940G>A, p.Glu314Lys) in CYP11A1 in 19 individuals from 13 different families (allele frequency within undiagnosed PAI in our cohort 0.102 vs 0.0026 in gnomAD, pA, Thr330=; c.1173C>T, Ser391=). Although p.Glu314Lys is predicted to be benign and showed no loss-of-function in an E. coli assay system, in silico and in vitro studies revealed that the rs6161/c.940G>A variant, plus the c.990G>A and c.1173C>T changes, affect splicing and that p.Glu314Lys produces a non-functional protein in mammalian cells. Taken together, these findings show that compound heterozygosity involving a relatively common and predicted “benign” variant in CYP11A1 is a significant contributor to PAI of unknown etiology, especially in European populations. These observations have implications for personalized management and demonstrate how variants that might be overlooked in standard analyses can be pathogenic when in combination with other very rare disruptive changes.
- 30 October 2018
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 3 (1) , 201-221
Open AccessPredicted Benign and Synonymous Variants in CYP11A1 Cause Primary Adrenal Insufficiency Through Missplicing
Primary adrenal insufficiency (PAI) is a potentially life-threatening condition that can present with non-specific features and can be difficult to diagnose. Here, we undertook next-generation sequencing in a cohort of children and young adults with PAI of unknown etiology from around the world and identified a heterozygous missense variant (rs6161, c.940G>A, p.Glu314Lys) in CYP11A1 in 19 individuals from 13 different families (allele frequency within undiagnosed PAI in our cohort 0.102 vs 0.0026 in gnomAD, pA, Thr330=; c.1173C>T, Ser391=). Although p.Glu314Lys is predicted to be benign and showed no loss-of-function in an E. coli assay system, in silico and in vitro studies revealed that the rs6161/c.940G>A variant, plus the c.990G>A and c.1173C>T changes, affect splicing and that p.Glu314Lys produces a non-functional protein in mammalian cells. Taken together, these findings show that compound heterozygosity involving a relatively common and predicted “benign” variant in CYP11A1 is a significant contributor to PAI of unknown etiology, especially in European populations. These observations have implications for personalized management and demonstrate how variants that might be overlooked in standard analyses can be pathogenic when in combination with other very rare disruptive changes.
- 18 October 2018
- Published by Bioscientifica in Endocrine Abstracts
Implementation of a novel non-invasive test for monitoring control in individuals with congenital adrenal hyperplasia
Introduction: Monitoring of hormonal control represents a key part in the management of congenital adrenal hyperplasia (CAH). It remains suboptimal and relies on frequent blood tests, which are traumatising in children and young persons (CYP). Recent evidence suggests a crucial role of adrenal-derived 11-oxygenatedC19 androgens in the pathogenesis of CAH. Therefore, we aimed to establish a non-invasive test for monitoring of adrenal-specific androgens in CAH. Objective: To establish the correlation between plasma and salivary androgens in CYP with CAH. Patients and methods: Patients (n=78, 43 girls, 35 boys, 8–18 years (12.87±3.04 years) and matched controls (n=62) were recruited in a multicentre prospective study of CYP with CAH across the United Kingdom. Using liquid chromatography tandem mass spectrometry, we measured plasma and salivary concentrations for five steroid hormones: 17-hydroxyprogesterone, androstenedione, testosterone, 11-hydroxyandrostenedione and 11-ketotestosterone and established the correlation (Spearman) between plasma and salivary steroids to assess their usefulness in clinical practice. Results: Plasma and salivary steroid concentrations show a good correlation, with androstenedione and 11-ketotestosterone providing the best information when used as non-invasive measurement from saliva: androstenedione (rs=0.928, Prs=0.864, Prs=0.871, Prs=0.877, Prs=0.944, P<0.001). In addition, a high correlation was found in CYP with CAH when analysing subgroups based on gender and age. Clear differences were found for all plasma and salivary steroids between patients and controls. Analysing patients according to CAH control by 17-hydroxyprogesterone concentrations (30 nmol/l), established clear correlations with plasma and salivary 11-ketotestosterone. Conclusions: We have established close correlation between plasma and salivary concentrations of steroid hormones assessed for therapy control in CAH patients. Importantly, the best correlations were found for the adrenal-derived 11oxygenatedC19 androgen 11-ketotestosterone as well as 17-hydroxyprogesterone and androstenedione, which are widely used for CAH monitoring. Thus, we believe that this novel and improved combination of salivary steroid hormones can serve as a non-invasive monitoring tool in CAH providing a significant amount of additional information, and will ultimately improve patient acceptability, management and outcomes in CAH.
- 18 October 2018
- Published by Bioscientifica in Endocrine Abstracts
Implementation of a novel non-invasive test for monitoring control in individuals with congenital adrenal hyperplasia
Introduction: Monitoring of hormonal control represents a key part in the management of congenital adrenal hyperplasia (CAH). It remains suboptimal and relies on frequent blood tests, which are traumatising in children and young persons (CYP). Recent evidence suggests a crucial role of adrenal-derived 11-oxygenatedC19 androgens in the pathogenesis of CAH. Therefore, we aimed to establish a non-invasive test for monitoring of adrenal-specific androgens in CAH. Objective: To establish the correlation between plasma and salivary androgens in CYP with CAH. Patients and methods: Patients (n=78, 43 girls, 35 boys, 8–18 years (12.87±3.04 years) and matched controls (n=62) were recruited in a multicentre prospective study of CYP with CAH across the United Kingdom. Using liquid chromatography tandem mass spectrometry, we measured plasma and salivary concentrations for five steroid hormones: 17-hydroxyprogesterone, androstenedione, testosterone, 11-hydroxyandrostenedione and 11-ketotestosterone and established the correlation (Spearman) between plasma and salivary steroids to assess their usefulness in clinical practice. Results: Plasma and salivary steroid concentrations show a good correlation, with androstenedione and 11-ketotestosterone providing the best information when used as non-invasive measurement from saliva: androstenedione (rs=0.928, Prs=0.864, Prs=0.871, Prs=0.877, Prs=0.944, P<0.001). In addition, a high correlation was found in CYP with CAH when analysing subgroups based on gender and age. Clear differences were found for all plasma and salivary steroids between patients and controls. Analysing patients according to CAH control by 17-hydroxyprogesterone concentrations (30 nmol/l), established clear correlations with plasma and salivary 11-ketotestosterone. Conclusions: We have established close correlation between plasma and salivary concentrations of steroid hormones assessed for therapy control in CAH patients. Importantly, the best correlations were found for the adrenal-derived 11oxygenatedC19 androgen 11-ketotestosterone as well as 17-hydroxyprogesterone and androstenedione, which are widely used for CAH monitoring. Thus, we believe that this novel and improved combination of salivary steroid hormones can serve as a non-invasive monitoring tool in CAH providing a significant amount of additional information, and will ultimately improve patient acceptability, management and outcomes in CAH.